Clinical Trial Update: Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes? [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether dapagliflozin can regress left ventricular hypertrophy in patients with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Left Ventricular Hypertrophy
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: University of Dundee | Conditions: Type 2 Diabetes, Left Ventricular Hypertrophy | Phase 4 | Status: COMPLETED